CCL17 and cancer: Next, to investigate whether the CCL17/CCL22-CCR4 interaction is mainly responsible for GRP78 induction in CRC cells, we pre-neutralized the CRC cancer cells with either CCR4 antibody or its antagonist, and found that TAMs-CM-T failed to induce GRP78 upregulation under both conditions (lines 6 and 8, Fig. 3J).